Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NT5E | P21589 | 3/20 | 0.37 |
| ▸ | PNP | P00491 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.31 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17114354 | 1.00 | NT5E (0.37) | NT5EPNPLMNATP53HTT | |
| SCHEMBL17106784 | 0.89 | AHCY (0.30) | — | |
| SCHEMBL17106685 | 0.85 | PRMT5 (0.40) | — | |
| SCHEMBL17106744 | 0.84 | NT5E (0.38) | NT5EPNPLMNATP53HTT | |
| SCHEMBL17111296 | 0.84 | NT5E (0.38) | NT5EPNPLMNATP53HTT | |
| SCHEMBL17111270 | 0.84 | NT5E (0.38) | NT5EPNPLMNATP53HTT | |
| SCHEMBL17106711 | 0.83 | PDE4D (0.45) | NT5EPNPLMNATP53HTT | |
| SCHEMBL17131313 | 0.82 | NT5E (0.37) | NT5EPNPLMNATP53HTT | |
| SCHEMBL17114355 | 0.75 | NT5E (0.34) | NT5EPNPLMNATP53HTT | |
| SCHEMBL17111236 | 0.75 | NT5E (0.34) | NT5EPNPLMNATP53HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180002366-A1 | 4'-SUBSTITUTED NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2018-01-04 | — | — | US | disclosed |
| US-9777035-B2 | 4′-substituted nucleoside reverse transcriptase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2017-10-03 | — | — | US | disclosed |
| US-20150274767-A1 | 4'-SUBSTITUTED NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2015-10-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180002366-A1 | 4'-SUBSTITUTED NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS | DUT, HPRT1, RNGTT | NT5E 217/4885PNP 5/4885LMNA 2821/4885 |
| US-20150274767-A1 | 4'-SUBSTITUTED NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS | DUT, HPRT1, RNGTT | NT5E 217/4885PNP 5/4885LMNA 2821/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.